Biotech News
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
investors.medicinova.com2026-05-06 15:07 EST
LA JOLLA, Calif. , Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc. , a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its